Gurugram: Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) today announced the audited financial results for the quarter and year ended March 31, 2026.
Q4 & FY26 Key Highlights:
Strategic Highlights
• Proposed Buyback – Up to 16 lakh equity shares (2.4% of total equity; 7.3% of non-promoter holding) at ₹250 per share with a total outlay of ₹40 Cr. Promoters shall not be participating in the same. This shall result in improvement of ROCE from 22.0% to 25.7% as well as ROE from 16.2% to 18.9%, reinforcing disciplined capital allocation and enhancing long-term shareholder value creation
• Enhanced dividend – Board has recommended higher dividend distribution at 200% (including 75% special dividend), resulting in a total cash outlay of ~₹262 Mn to shareholders
Financial Highlights
• Topline trajectory driven by strong internal execution and demand momentum – While Q4 revenue growth accelerated to ~10% on YoY basis, it grew by ~7% to ₹2,872 Mn.
• Operational discipline sustains EBITDA Margins- Op. EBITDA of ₹ 609 Mn for the full year with the margin of 21.2% while for Q4 EBITDA stood at ₹106 Mn, demonstrating efficient operating discipline.
• Strong growth in net profits – Operational PAT rose to ₹ 88 Mn in Q4 up 31%, while full year grew by 19% to ₹ 446 Mn on a YoY basis, with the margin of 15.5% underscoring sustained profitability momentum.
• Robust cash flow generation – Cash balance stood at ₹1,907 Mn as of Mar 31, 2026, an uptick of ₹ 451 Mn underscoring strong operational and financial discipline.
Manish Gupta, Managing Director and CEO, Jagsonpal Pharmaceuticals Limited said, “Our business regained traction in Q4 with growth of 10% on strength of sharper strategic execution. This is reflecting in our industry outpacing performance, with Pharmarack reflecting a 12.2% growth for Jagsonpal as compared to IPM growth of 8.6%. Our ‘Top 10’ brands which account for~58% of revenues continue to drive performance. Our yearly revenues grew 7% while our operating net profit grew 19% in the same period, with the year closing with a healthy cash position of ₹191 crores. The Board has recommended a dividend of 200% (including a special dividend of 75%) for FY26. We will shortly be launching the proposed ₹40 crore buy-back at ₹250 per share as we received shareholder approval today. These shareholders-centric actions are reflective of our confidence in growth momentum of business in FY27 and beyond, with continued strong cash generation and improving ROCE/ROE. We are confident of continued acceleration on all parameters given our focus on organic growth through improved MR productivity, strengthening key brands, and launching strategic new products, even as we look for value-accretive inorganic opportunities.”
